In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer

Improving effector activity of antigen-specific T cells is a major goal in cancer immunotherapy. Despite the identification of several effector T cell (T-EFF)-driving transcription factors (TFs), the transcriptional coordination of T-EFF biology remains poorly understood. We developed an in vivo T cell CRISPR screening platform and identified a key mechanism restraining T-EFF biology through the ETS family TF, Fli1. Genetic deletion of Fli1 enhanced T-EFF responses without compromising memory or exhaustion precursors. Fli1 restrained T-EFF lineage differentiation by binding to cis-regulatory elements of effector-associated genes. Loss of Fli1 increased chromatin accessibility at ETS:RUNX motifs, allowing more efficient Runx3-driven T-EFF biology. CD8(+) T cells lacking Fli1 provided substantially better protection against multiple infections and tumors. These data indicate that Fli1 safeguards the developing CD8(+) T cell transcriptional landscape from excessive ETS:RUNX-driven T-EFF cell differentiation. Moreover, genetic deletion of Fli1 improves T-EFF differentiation and protective immunity in infections and cancer.

Automated summary

Improving the effector activity of antigen-specific T cells is a major goal in cancer immunotherapy. Although several effector T cell-driving transcription factors have been identified, the transcriptional coordination of T-EFF biology remains poorly understood. This study shows that genetic deletion of Fli1 enhances T-EFF responses by restraining T-EFF lineage differentiation.